Hologic Inc., a leading developer and manufacturer of medical products, recently announced its financial results for the third quarter of 2023. The company experienced a slight decline in revenue, with a year-over-year decrease of 1.8% to $984.4 million. This decrease can be attributed to lower sales of COVID-19 assays compared to the previous year. However, despite this decline, the revenue surpassed the company’s initial guidance of $930-$980 million and the consensus estimate of $957.13 million.
Diagnostics sales saw a significant dip of 21.5%, primarily due to the decrease in demand for COVID-19-related products. However, when excluding these products, diagnostics sales actually grew by 11.8% on an organic, constant currency basis. On the other hand, Breast Health revenue experienced a notable increase of 27.4%. This growth was primarily driven by higher capital equipment revenue, as the semiconductor chip supply environment improved, allowing for more gantry deliveries. Additionally, surgical revenue grew by 13.9%, mainly due to the success of the company’s hysteroscopic portfolio.
In terms of profitability, Hologic reported a decrease in non-GAAP gross margin, which dropped by 250 basis points to 60.8%. Similarly, the non-GAAP operating margin decreased by 340 basis points to 28.9%.
Looking ahead to the full fiscal year 2023, Hologic projects revenue in the range of $3.995 to $4.035 billion. This is an increase compared to the previously expected range of $3.925-$4.025 billion and the consensus estimate of $4.02 billion. The company also expects adjusted earnings per share (EPS) in the range of $3.87 to $3.94, surpassing the consensus estimate of $3.91 and the earlier guidance of $3.75-$3.95.
For the fourth quarter of fiscal year 2023, Hologic anticipates revenues between $910 and $950 million, with adjusted EPS in the range of $0.80 to $0.87. These figures fall slightly below the consensus estimate of $951.07 million in revenue and an EPS of $0.87.
Despite the revenue exceeding the company’s prior guidance, Hologic’s stock experienced a decline of 3.27% and was valued at $76.82 on August 1, 2023.
Updated on: 03/12/2023
Debt to equity ratio: Buy
Price to earnings ratio: Strong Buy
Price to book ratio: Strong Buy
DCF: Strong Buy
We did not find social sentiment data for this stock
|Analyst / firm||Rating|
|Cowen & Co.||Buy|
Hologic Inc. (HOLX) Stock Performance Declines on August 1, 2023: Trading Volume Hits Record Low
On August 1, 2023, Hologic Inc. (HOLX) experienced a decline in its stock performance. The stock opened at $73.56, which was lower than the previous day’s closing price of $79.45. Throughout the day, the stock traded in a range between $73.55 and $77.20. The trading volume for the day was 172,346 shares, significantly lower than the average volume of 1,448,606 shares over the past three months.
Hologic Inc. (HOLX) Stock Performance and Potential Growth: Analysts Price Forecasts and Recommendations
Hologic Inc. (HOLX) is a company that specializes in medical technology and diagnostic solutions. On August 1, 2023, the stock’s performance was closely monitored by investors and analysts. According to data from CNN Money, the 14 analysts who offered 12-month price forecasts for HOLX had a median target of $93.00, with a high estimate of $98.00 and a low estimate of $80.00. This median estimate indicated a potential increase of 21.31% from the last recorded price of $76.66.
The consensus among 20 polled investment analysts was to hold stock in Hologic Inc. This rating has remained steady since July, indicating that there has been no significant change in the overall sentiment towards the stock. Investors are advised to closely monitor any updates or changes in the rating as it may impact their investment decisions.
Hologic Inc. is a well-established player in the medical technology industry, known for its innovative solutions in areas such as breast health, diagnostics, and surgical products. The company’s products and services cater to a wide range of healthcare professionals and institutions, making it an important player in the healthcare sector.
Investors and analysts are closely watching HOLX stock due to its potential for growth. The median target price of $93.00 suggests that analysts are optimistic about the stock’s future performance, expecting a significant increase in value over the next 12 months. However, it is important to note that these forecasts are based on various factors and are subject to change as market conditions evolve.
Overall, HOLX stock’s performance on August 1, 2023, was closely monitored by investors and analysts. With a consensus hold rating and a median target price indicating potential growth, investors are advised to stay updated on any developments regarding Hologic Inc.’s financial performance and market sentiment.